Drugs / COMBIG-DC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01974661 | Oct 2013 → Jun 2017 | hepatocellular carcinoma | Mendus | Completed | No outcome recorded |
| Phase 1 | NCT01525017 | Feb 2012 → Dec 2013 | renal cell carcinoma | Mendus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COMBIG-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01974661 ↗ |
| Modality | Cell therapy | “a cellular adjuvant consisting of pre-activated allogeneic DCs” PMID 28642820 ↗ Jun 2017 |
| Route | Other | “INTUVAX) was injected into the renal tumor twice with 2 weeks interval” PMID 28642820 ↗ Jun 2017 |